/
We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis del…
The business is unprofitable at the operating level (-16.76% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 153.5% YoY with margins expanding 142.5pp.
Negative free cash flow of -$41M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$71M
▲ +153.5% YoY
Net Income (TTM)
-$6M
▲ +84.8% YoY
Op. Margin
-19.05%
▲ +142.5pp YoY
ROIC
-6.94%
▲ +82.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$40M
▲ +19.5% YoY
Op. Cash Flow (TTM)
-$40M
▲ +19.6% YoY
Net Debt
-$224M
Net Cash Position
Cash & Equiv.
$227M
5Y CAGR: -1.8%
Continue Research